Reports

Ideas That Generate Results

US Cancer Vaccine Market Outlook 2022

US Cancer Vaccine Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jul, 2016| No. of Pages : 135

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1200.00
CD-ROM Mail Delivery
US$ 1400.00
Hard Copy Mail Delivery
US$ 1400.00
Electronic Access - Multi-User License
US$ 2000.00

1. Analyst View

2. Research Methodology

3. Cancer Statistics by Demographics
     3.1 Prevalence, Incidences and Mortality
     3.2 Leading States by Incidences
     3.3 Leading Cancers by Incidences
            3.3.1 Male Cancer Incidences
            3.3.2 Female Cancer Incidences
            3.3.3 Children Cancer Incidences

4. Market Dynamics
     4.1 Drivers
            4.1.1 Rising Cancer Incidences
            4.1.2 Ability to Reduce Healthcare Expenditure
            4.1.3 Rising Awareness
            4.1.4 Patient Assistance Programs
            4.1.5 Government Initiatives
            4.1.6 Strong Pipeline
            4.1.7 Technological Advancements
     4.2 Restraints
            4.2.1 High Cost of Cancer Vaccines
            4.2.2 Side Effects of Cancer Vaccines
            4.2.3 Vaccine Supply Shortages
            4.2.4 Insurance Issues Related to Cancer Vaccination
     4.3 Opportunities
            4.3.1 Therapeutic Cancer Vaccines
            4.3.2 Adjuvant Cancer Vaccines

5. Cancer Vaccines Market Outlook
     5.1 Key Product Analysis
            5.1.1 Provenge
                       5.1.1.1 Market Analysis
            5.1.2 T-Vec/Imlygic
                       5.1.2.1 Market Analysis
            5.1.3 HPV Vaccine
                       5.1.3.1 Gardasil
                                      5.1.3.1.1 Market Analysis
                       5.1.3.2 Cervarix
                                      5.1.3.2.1 Market Analysis
            5.1.4 HBV Vaccines
                       5.1.4.1 Engerix-B
                                     5.1.4.1.1 Market Analysis
                       5.1.4.2 Recombivax HB
                                     5.1.4.2.1 Market Analysis
                       5.1.4.3 Pediarix/ Infanrix
                                     5.1.4.3.1 Market Analysis

6. Cancer Vaccines Market by Cancer Type

7. Cancer Vaccine Market by Application

8. Potential Cancer Vaccine Candidates: An Opportunity Assessment
     8.1 Prophylactic Vaccine
     8.2 Therapeutic Vaccine
            8.2.1 Prostate Cancer
            8.2.2 Breast Cancer
            8.2.3 Lung Cancer
            8.2.4 Colorectal Cancer

9. US Patent Analysis
     9.1 Patents by Year
     9.2 Patents by Category
            9.2.1 Utility Patents
            9.2.2 Design Patents
            9.2.3 Plant Patents
     9.3 Patents by Company
     9.4 Patents by Assignee Type
            9.4.1 By Assignee Name
            9.4.2 By Assignee State

10. Regulatory Environment
       10.1 Vaccine Approval Process
       10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
                10.2.1 Considerations for both Early and Late Phase Clinical Trials
                             10.2.1.1 Patient Population
                             10.2.1.2 Monitoring the Immune Response
                             10.2.1.3 Biomarkers as Evidence of Efficacy
                             10.2.1.4 Adjuvants Used to Stimulate Immune Response
                             10.2.1.5 Multi-antigen Vaccines
                             10.2.1.6 Disease Progression/Recurrence Immediately or Shortly
                                          after the Initial Administration of Cancer Vaccines
                             10.2.1.7 Concomitant and Subsequent Therapies
                10.2.2 Considerations for Early Phase Clinical Trials
                             10.2.2.1 Starting Dose and Dosing Schedule
                             10.2.2.2 Booster and Maintenance Therapy
                             10.2.2.3 Dose Escalation
                             10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early
                                          Development
                10.2.3 Considerations for Late Phase Clinical Trials
                             10.2.3.1 Safety Profile from Early Phase Clinical Trials
                             10.2.3.2 Endpoints
                             10.2.3.3 Statistical Issues
                             10.2.3.4 Control Issues
                             10.2.3.5 Delayed Vaccine Effect
                             10.2.3.6 Autologous Vaccine Trials
                             10.2.3.7 Accelerated Approval Regulations

11. Competitive Landscape

12. Company Profiles
       12.1 Merck & Co.
       12.2 GlaxoSmithKline plc
       12.3 Dendreon (A Subsidiary of Valeant Pharmaceuticals)
       12.4 Amgen Inc. 

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.